The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Improving the accuracy of infection reporting in myeloma clinical trials
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses the increased infection risk in patients with multiple myeloma (MM) who are treated with immunotherapy. He highlights the bias in infection reporting in clinical trials and suggests recording infections per patient per month and accounting for varying study durations to improve accuracy. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Amgen, Takeda, Sanofi
Speaker‘s Bureau, Advisory Boards: Amgen, Takeda, Celgene-BMS, Janssen, Pfizer, Sanofi
